[go: up one dir, main page]

WO2015153864A3 - Méthodes de traitement d'états inflammatoires - Google Patents

Méthodes de traitement d'états inflammatoires Download PDF

Info

Publication number
WO2015153864A3
WO2015153864A3 PCT/US2015/024047 US2015024047W WO2015153864A3 WO 2015153864 A3 WO2015153864 A3 WO 2015153864A3 US 2015024047 W US2015024047 W US 2015024047W WO 2015153864 A3 WO2015153864 A3 WO 2015153864A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
methods
inflammatory
inflammatory conditions
detecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/024047
Other languages
English (en)
Other versions
WO2015153864A2 (fr
Inventor
Patricia T. HOPKINS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2015153864A2 publication Critical patent/WO2015153864A2/fr
Publication of WO2015153864A3 publication Critical patent/WO2015153864A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes de traitement de sujets souffrant d'états inflammatoires, tels que lésions traumatiques légères du cerveau (mTBI), arthrose (OA), et fibromyalgie. Lesdites méthodes peuvent consister à déterminer si le sujet présente un tel état inflammatoire et à administrer une quantité efficace d'un composé de tétracycline (par exemple, la doxycycline) audit sujet (par exemple, un humain) L'invention concerne également des procédés permettant de détecter un état inflammatoire chez un sujet en déterminant un niveau d'un biomarqueur inflammatoire, tel que le TGF-βΙ, dans un échantillon biologique (par exemple, du sang) prélevé sur le sujet. De tels procédés peuvent également être utilisés en tant que diagnostic compagnon en combinaison avec un traitement de tétracycline pour évaluer l'efficacité d'un traitement. En outre, l'invention concerne des kits permettant de détecter et de traiter de tels états inflammatoires.
PCT/US2015/024047 2014-04-02 2015-04-02 Méthodes de traitement d'états inflammatoires Ceased WO2015153864A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461974118P 2014-04-02 2014-04-02
US61/974,118 2014-04-02
US201462074327P 2014-11-03 2014-11-03
US62/074,327 2014-11-03

Publications (2)

Publication Number Publication Date
WO2015153864A2 WO2015153864A2 (fr) 2015-10-08
WO2015153864A3 true WO2015153864A3 (fr) 2015-11-12

Family

ID=54241442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/024047 Ceased WO2015153864A2 (fr) 2014-04-02 2015-04-02 Méthodes de traitement d'états inflammatoires

Country Status (1)

Country Link
WO (1) WO2015153864A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
JP2006505583A (ja) 2002-10-25 2006-02-16 フォーミックス エルティーディー． 化粧剤および医薬用フォーム
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (fr) 2007-12-07 2009-06-11 Foamix Ltd. Porteurs, formulations, procédés pour formuler des agents actifs instables pour application externe et utilisations associées
WO2010125470A2 (fr) 2009-04-28 2010-11-04 Foamix Ltd. Véhicule moussant et compositions pharmaceutiques comportant des solvants polaires aprotiques et leurs utilisations
CA2769677A1 (fr) 2009-07-29 2011-02-03 Foamix Ltd. Compositions hydro-alcooliques moussantes a base d'agents non tensioactifs non polymeres, mousses legeres, et leurs utilisations
CA2769625C (fr) 2009-07-29 2017-04-11 Foamix Ltd. Compositions hydro-alcooliques moussantes non tensioactives, mousses legeres, et leurs utilisations
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
MX359879B (es) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
GB201603967D0 (en) 2016-03-08 2016-04-20 Univ Birmingham Biomarkers of traumatic brain injury
MX377365B (es) 2016-09-08 2025-03-10 Journey Medical Corp Composiciones y métodos para tratar rosácea y acné.
GB201914847D0 (en) * 2019-10-14 2019-11-27 Helperby Therapeutics Ltd Combination
US20240344131A1 (en) * 2023-03-13 2024-10-17 Center for Immunology Science Genomic signatures of fibromyalgia and chronic pain and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007133586A2 (fr) * 2006-05-08 2007-11-22 Tethys Bioscience, Inc. Systèmes et procédés destinés à développer des tests diagnostiques sur la base d'informations de biomarqueurs provenant d'ensembles d'échantillons cliniques existants
WO2008046508A1 (fr) * 2006-10-16 2008-04-24 Bayer Healthcare Ag Facteur tgfb2 utilisé en tant que biomarqueur, cible thérapeutique et diagnostique
US20080233206A1 (en) * 2007-03-23 2008-09-25 Molecular Research Center, Inc. Compositions and methods for anti-inflammatory treatments
US7611702B2 (en) * 2005-11-08 2009-11-03 Medarex, Inc. TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
US7691839B2 (en) * 2005-09-28 2010-04-06 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US20130011849A1 (en) * 2007-01-31 2013-01-10 Henkin Robert I Methods for Detection of Biological Substances

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691839B2 (en) * 2005-09-28 2010-04-06 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US7611702B2 (en) * 2005-11-08 2009-11-03 Medarex, Inc. TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
WO2007133586A2 (fr) * 2006-05-08 2007-11-22 Tethys Bioscience, Inc. Systèmes et procédés destinés à développer des tests diagnostiques sur la base d'informations de biomarqueurs provenant d'ensembles d'échantillons cliniques existants
WO2008046508A1 (fr) * 2006-10-16 2008-04-24 Bayer Healthcare Ag Facteur tgfb2 utilisé en tant que biomarqueur, cible thérapeutique et diagnostique
US20130011849A1 (en) * 2007-01-31 2013-01-10 Henkin Robert I Methods for Detection of Biological Substances
US20080233206A1 (en) * 2007-03-23 2008-09-25 Molecular Research Center, Inc. Compositions and methods for anti-inflammatory treatments

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"ACTAVIS 2014 Investor Meeting.", POWERPOINT PRESENTATION, 31 January 2014 (2014-01-31), pages 1 - 133, Retrieved from the Internet <URL:http://phx.corporate-ir.net/External.File?t=1&item=VHIwZT0yfFBhcmVudEIEPTUwODA3NDh8Q2hpbGRJRD01MzEyNjY=> [retrieved on 20150614] *
BUTLER ET AL.: "Antibiotics in the clinical pipeline in 2013", THE JOUMAL OF ANTIBIOTICS, vol. 66, 4 September 2013 (2013-09-04), pages 517 - 591 *
LYKE ET AL.: "Serum Levels of the Proinflammatory Cytokines Interleukin-1 Beta ( IL -1 beta), IL -6, IL -8, IL -10, Tumor Necrosis Factor Alpha, and IL -12(p70) in Malian Children with Severe Plasmodium falciparum Malaria and Matched Uncomplicated Malaria or Healthy Controls", INFECTION AND IMMUNITY, vol. 72, no. 10, October 2004 (2004-10-01), pages 5630 - 5637 *
NICOLETTI ET AL.: "Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b", CLINICAL EXPERIMENTAL IMMUNOLOGY, vol. 113, July 1998 (1998-07-01), pages 96 - 99 *
PATTERSON ET AL.: "Understanding the neuroinflammatory response following concussion to develop treatment strategies", FRONTIERS IN CELLULAR NEUROSCIENCE, vol. 6, 22 October 2012 (2012-10-22), pages 1 - 10 *
POSTHUMUS ET AL.: "Serum levels of matix metaaloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis", RHEUMATOLOGY, vol. 38, no. 11, November 1999 (1999-11-01), pages 1081 - 1087 *
REKAS ET AL.: "Malignant Glaucoma", INTECH, 3 March 2014 (2014-03-03), pages 421 - 438, XP055235674, Retrieved from the Internet <URL:http://cdn.intechopen.com/pdfs-wm/44164.pdf> [retrieved on 20150614] *
RICE ET AL.: "Manual Physical Therapy for Non-Surgical Treatment of Adhesion-Related Small Bowel Obstructions: Two Case Reports", JOUMAL OF CLINICAL MEDICINE, vol. 2, 4 February 2013 (2013-02-04), pages 1 - 12, XP055235671 *
WONG ET AL.: "Epidemiology of Cytokines The Women On the Move through Activity and Nutrition (WOMAN) Study", AMERICAN JOURNAL OF EPIDEMIOLOGY, vol. 168, no. 04, 25 June 2008 (2008-06-25), pages 443 - 453 *

Also Published As

Publication number Publication date
WO2015153864A2 (fr) 2015-10-08

Similar Documents

Publication Publication Date Title
WO2015153864A3 (fr) Méthodes de traitement d&#39;états inflammatoires
EA201690969A1 (ru) Способы и композиции для лечения связанных со старением состояний
EP3865135A3 (fr) Stéroïdes neuroactifs destinés à l&#39;utilisation thérapeutique
EP4257705A3 (fr) Biomarqueurs de traumatisme cranio-cérébral
EA201400491A1 (ru) Сопровождающая диагностика для терапии с антигиалуроновым агентом и способы ее применения
BR112013022493A2 (pt) equipamento e método para examinar, diagnosticar ou auxiliar no diagnóstico e no tratamento de problemas funcionais de visão
WO2017181079A3 (fr) Méthodes de surveillance et de traitement du cancer
BR112014018592A2 (pt) composição e método para o diagnóstico e tratamento de doenças associadas à degeneração de neuritos
WO2015094995A3 (fr) Biomarqueurs de signature génique de réponse tumorale à des antagonistes de pd-1
EP3294124A4 (fr) Système et procédés pour le diagnostic précoce de troubles du spectre de l&#39;autisme
WO2013128293A3 (fr) Méthodes, appareils et systèmes permettant de diagnostiquer et de traiter des troubles de l&#39;humeur
EP3376939A4 (fr) Procédés automatisés de quantification objective des caractéristiques rétiniennes par région rétinienne et diagnostic d&#39;une rétinopathie
WO2016040891A3 (fr) Compositions in vitro comprenant un échantillon humain et un agent ciblant les substances amyloïdes
MX382410B (es) Determinación de niveles de glicosaminoglicanos mediante espectrometría de masas.
WO2017031067A3 (fr) Biomarqueurs pour le traitement de la pelade
WO2015013508A3 (fr) Procédés permettant de diagnostiquer et de traiter une maladie du système immunitaire
EP3347492A4 (fr) Procédés pour le diagnostic histologique et le traitement de maladies
WO2015164431A3 (fr) Processus, procédés, dispositifs et kits pour la mesure de marqueurs du stress post-traumatique de type microarn
WO2015148389A3 (fr) Diagnostic de la sclérose en plaques chez des sujets humains et animaux
WO2016117969A3 (fr) Dispositif de traitement par la lumière utilisant l&#39;analyse d&#39;image de lésion, procédé de détection de site de lésion par analyse d&#39;image de lésion utilisé à cet effet, et supports d&#39;enregistrement lisibles par dispositif informatique comprenant ledit procédé enregistré
MX387627B (es) Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia
MX2018000528A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
WO2015038634A3 (fr) Dosage diagnostique multiplex pour la maladie de lyme et d&#39;autres maladies transmises par les tiques
WO2016168344A8 (fr) Procédé et système pour la caractérisation, le diagnostic et le traitement dérivés du microbiome d&#39;affections associées à des caractéristiques fonctionnelles
MX385216B (es) Prueba de diagnostico basada en fragmento de rgma.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15773101

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15773101

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 19/04/2017)

122 Ep: pct application non-entry in european phase

Ref document number: 15773101

Country of ref document: EP

Kind code of ref document: A2